Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

By J. Heffelfinger, S. Dowell, J. Jorgensen, K. Klugman, Leah R. Mabry, D. Musher, J. Plouffe, A. Rakowsky, A. Schuchat, C. Whitney. Archives of Internal Medicine, 2000

641 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Epidemiology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/d0724d1f874b4eb70b73b435bc221b607ddf7aa0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Mandell
2. R. Wunderink
3. A. Anzueto
4. J. Bartlett
5. G. Campbell
6. S. Dowell
7. Nathan C. Dean
8. D. Musher

Citations in the corpus

• Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults (2003, background): “The new breakpoints acknowledge that nonmeningeal infections caused by strains formerly considered to be intermediately susceptible and even some that were regarded as resistant can be treated successfully with the usual doses of b-lactam drugs [21] [22] [23] [24] [25] [26] .”
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “The use of fluoroquinolones to treat ambulatory patients with CAP without comorbid conditions, risk factors for DRSP, or recent antimicrobial use is discouraged because of concern that widespread use may lead to the development of fluoroquinolone resistance [185] .”